Roivant Sciences (NASDAQ:ROIV) Director Sells 625,783 Shares of Stock

Key Points

• Roivant Sciences director Daniel Allen Gold sold 625,783 shares on June 26 at an average price of $34.00, totaling about $21.3 million. The sale reduced his direct stake by 4.14%, though he still owns 14.5 million shares.
• Gold also made two additional large sales in the following days, including 800,000 shares on June 29 and 12,380 shares on June 30. Those trades added roughly $28.1 million in proceeds combined.
• ROIV shares have been strong recently, trading up 1.9% to $35.39 and near their 52-week high of $35.90. Analyst sentiment remains broadly positive, with a consensus rating of “Moderate Buy” and a price target of $33.59.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $34.00, for a total transaction of $21,276,622.00. Following the transaction, the director directly owned 14,501,546 shares in the company, valued at $493,052,564. The trade was a 4.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Daniel Allen Gold also recently made the following trade(s):

• On Tuesday, June 30th, Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock. The shares were sold at an average price of $35.28, for a total value of $436,766.40.
• On Monday, June 29th, Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.55, for a total value of $27,640,000.00.

Roivant Sciences Trading Up 1.9%

Shares of NASDAQ ROIV traded up $0.66 during mid-day trading on Tuesday, reaching $35.39. 6,160,114 shares of the company's stock were exchanged, compared to its average volume of 5,917,255. Roivant Sciences Ltd. has a twelve month low of $10.70 and a twelve month high of $35.90. The firm has a market capitalization of $25.45 billion, a price-to-earnings ratio of -58.98 and a beta of 1.13. The business has a fifty day simple moving average of $29.88 and a 200 day simple moving average of $27.02.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million during the quarter, compared to analysts' expectations of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period in the prior year, the business earned ($0.29) EPS. Equities research analysts predict that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors have recently made changes to their positions in ROIV. Goldman Sachs Group Inc. grew its holdings in Roivant Sciences by 15.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company's stock worth $24,553,000 after acquiring an additional 324,764 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Roivant Sciences by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company's stock valued at $24,678,000 after acquiring an additional 34,341 shares during the period. American Century Companies Inc. lifted its position in shares of Roivant Sciences by 1.9% during the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company's stock valued at $1,010,000 after acquiring an additional 1,689 shares during the period. Russell Investments Group Ltd. increased its stake in Roivant Sciences by 149.9% in the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company's stock valued at $129,000 after purchasing an additional 6,879 shares in the last quarter. Finally, M&T Bank Corp raised its holdings in shares of Roivant Sciences by 10.2% during the second quarter. M&T Bank Corp now owns 12,802 shares of the company's stock valued at $144,000 after purchasing an additional 1,181 shares during the period. Institutional investors own 64.76% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on ROIV. Piper Sandler restated an "overweight" rating on shares of Roivant Sciences in a report on Thursday, May 21st. HC Wainwright reissued a "buy" rating and issued a $34.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Guggenheim increased their price target on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Tuesday, May 26th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Finally, Weiss Ratings downgraded shares of Roivant Sciences from a "sell (d)" rating to a "sell (d-)" rating in a report on Friday, May 22nd. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.